Amit P. Bhavsar

Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Adopting orphan receptors: zebrafish Tlr4 homologs mediate responses to group IX/X transition metals.

Adopting orphan receptors: zebrafish Tlr4 homologs mediate responses to group IX/X transition metals.

Journal: Frontiers in immunology
Published: August 04, 2025

The Salmonella Effector SspH2 Facilitates Spatially Selective Ubiquitination of NOD1 to Enhance Inflammatory Signaling.

The Salmonella Effector SspH2 Facilitates Spatially Selective Ubiquitination of NOD1 to Enhance Inflammatory Signaling.

Journal: Biochemistry
Published: August 27, 2024

TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.

TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.

Journal: The Journal of pharmacology and experimental therapeutics
Published: July 08, 2024

All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.

All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.

Journal: PloS one
Published: July 29, 2022

Cisplatin Toxicity Is Mediated by Direct Binding to Toll-Like Receptor 4 through a Mechanism That Is Distinct from Metal Allergens.

Cisplatin Toxicity Is Mediated by Direct Binding to Toll-Like Receptor 4 through a Mechanism That Is Distinct from Metal Allergens.

Journal: Molecular pharmacology
Published: July 18, 2022

Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.

Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.

Journal: International journal of molecular sciences
Published: May 31, 2022

TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

Journal: NPJ precision oncology
Published: October 08, 2020

Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity.

Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity.

Journal: EMBO reports
Published: July 09, 2020

Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity.

Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity.

Journal: NPJ genomic medicine
Published: October 25, 2019

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Journal: Clinical pharmacology and therapeutics
Published: March 01, 2019

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.

Journal: Pediatric blood & cancer
Published: May 30, 2017

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Journal: JAMA oncology
Published: April 28, 2017
Showing 1-12 of 26

Last Updated: 09/26/2026